Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.
N,N'-((4-(Dimethylamino)phenyl)methylene)bis(2-phenylacetamide) was discovered by using 3D pharmacophore database searches and was biologically confirmed as a new class of CB(2) inverse agonists. Subsequently, 52 derivatives were designed and synthesized through lead chemistry optimization by modifying the rings A-C and the core structure in further SAR studies. Five compounds were developed and also confirmed as CB(2) inverse agonists with the highest CB(2) binding affinity (CB(2)K(i) of 22-85 nM, EC(50) of 4-28 nM) and best selectivity (CB(1)/CB(2) of 235- to 909-fold). Furthermore, osteoclastogenesis bioassay indicated that PAM compounds showed great inhibition of osteoclast formation. Especially, compound 26 showed 72% inhibition activity even at the low concentration of 0.1 μM. The cytotoxicity assay suggested that the inhibition of PAM compounds on osteoclastogenesis did not result from its cytotoxicity. Therefore, these PAM derivatives could be used as potential leads for the development of a new type of antiosteoporosis agent.
Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh , Pittsburgh, Pennsylvania 15260, USA.
Peng
P
Yang
Kyaw-Zeyar
KZ
Myint
Qin
Q
Tong
Rentian
R
Feng
Haiping
H
Cao
Abdulrahman A
AA
Almehizia
Mohammed Hamed
MH
Alqarni
Lirong
L
Wang
Patrick
P
Bartlow
Yingdai
Y
Gao
Jürg
J
Gertsch
Jumpei
J
Teramachi
Noriyoshi
N
Kurihara
Garson David
GD
Roodman
Tao
T
Cheng
Xiang-Qun
XQ
Xie
D000478:Alkylation / Q000187:drug effects; D000818:Animals; D044482:Benzeneacetamides / Q000737:chemistry / Q000494:pharmacology*; D001667:Binding, Competitive; D001853:Bone Marrow / Q000187:drug effects*; D016466:CHO Cells; D016923:Cell Death; D002478:Cells, Cultured; D006224:Cricetinae; D000242:Cyclic AMP / Q000378:metabolism; D057166:High-Throughput Screening Assays; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects*; D010012:Osteogenesis / Q000187:drug effects*; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists* / Q000378:metabolism; D013329:Structure-Activity Relationship
D044482:Benzeneacetamides; C577951:N,N'-((4-(diethylamino)phenyl)methylene)bis(2-phenylacetamide); D043885:Receptor, Cannabinoid, CB2; C005293:2-phenylacetamide; D000242:Cyclic AMP